Patent · US Active

Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors

US9266891B2 · kind B2 · utility

2Cited by

0References

27Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Harald Engelhardt · Ebreichsdorf, AT
Davide Gianni · Wien, AT
Christian Alan Paul Smethurst · Wien, AT

Key dates

Filing date	Nov 11, 2013
Grant date	Feb 23, 2016
Priority date	—
Expiry date	Nov 11, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compounds of the formula (I)wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.